Patisiran, Inotersen Aid Hereditary Transthyretin Amyloidosis

Share this content:
Patisiran, Inotersen Aid Hereditary Transthyretin Amyloidosis
Patisiran, Inotersen Aid Hereditary Transthyretin Amyloidosis

THURSDAY, July 5, 2018 (HealthDay News) -- For patients with hereditary transthyretin amyloidosis with polyneuropathy, an investigational RNA interference therapeutic agent (patisiran) and a 2'-O-methoxyethyl-modified antisense oligonucleotide (inotersen), which inhibits hepatic production of transthyretin, improve clinical manifestations of disease, according to two studies published in the July 5 issue of the New England Journal of Medicine.

David Adams, M.D., Ph.D., from the Université Paris-Sud, and colleagues conducted a phase 3 trial involving patients with hereditary transthyretin amyloidosis with polyneuropathy receiving either patisiran (148 patients) or placebo (77 patients). The researchers found that the least-squares mean change from baseline in the modified Neuropathy Impairment Score+7 (mNIS+7) was −6.0 ± 1.7 versus 28.0 ± 2.6 in the patisiran versus the placebo group (difference, −34.0 points) at 18 months. The least-squares mean change from baseline in the Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire was −6.7 ± 1.8 versus 14.4 ± 2.7 (difference, −21.1 points) at 18 months.

Merrill D. Benson, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a randomized trial involving adults with stage 1 or 2 hereditary transthyretin amyloidosis with polyneuropathy. Patients were randomized to inotersen (112 patients) or placebo (60 patients). The researchers found that the difference in the least-squares mean change from baseline to week 66 favored inotersen versus placebo (−19.7 points for the mNIS+7 and −11.7 points for the Norfolk QOL-DN score).

"Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis," Bensen and colleagues write.

The Adams study was supported by Alnylam Pharmaceuticals; the Benson study was funded by Ionis Pharmaceuticals.

Abstract/Full Text - Adams (subscription or payment may be required)
Abstract/Full Text - Benson (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Salmonella Outbreak in 26 States Linked to Raw Turkey Products

<i>Salmonella</i> Outbreak in 26 States Linked to Raw ...

40 individuals have been hospitalized to date; no deaths have been reported

FDA Recalls Drugs Containing Active Ingredient Valsartan

FDA Recalls Drugs Containing Active Ingredient Valsartan

All lots of non-expired products that contain valsartan supplied by Zhejiang Huahai being recalled

Atopic Dermatitis Places Heavy Burden on Patients

Atopic Dermatitis Places Heavy Burden on Patients

Overall and mental health, life satisfaction all impacted, especially for moderate, severe disease

is free, fast, and customized just for you!




Already a member?

Sign In Now »